Department of Pharmacology, Lumbini Medical College and Teaching Hospital, Tansen, Palpa, Nepal.
Department of Pharmacology, Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
JNMA J Nepal Med Assoc. 2022 Dec 1;60(256):1016-1020. doi: 10.31729/jnma.7642.
Assessing anti-diabetic drug use patterns in hospitals is an important activity which helps to promote the rational use of drugs and may suggest measures to change prescribing habits for the better. This study aimed to find the use of combination therapy in diabetes mellitus patients attending the outpatient department of a tertiary care centre.
A descriptive cross-sectional study was conducted among 201 diabetes mellitus patients in the internal medicine department from 2 March 2022 to 30 June 2022 for a duration of four months after approval from the Institutional Review Committee (Protocol No: IRC-LMC-01/R-022). Diabetic patients prescribed at least one anti-diabetic drug in prescription forms were included. Socio-demographic profiles, clinical characteristics and anti-diabetic drug use pattern-related data were collected. Convenience sampling was used. Point estimate and 95% Confidence Interval were calculated.
Among 201 patients, 134 (66.66%) (60.14-73.18, 95% Confidence Interval) patients were given combination therapy. The most common combination therapy was metformin 500 mg and sitagliptin 50 mg. A total of 324 anti-diabetic drugs were used. The average number of drugs prescribed per patient was 1.6±0.7. The number of anti-diabetic drugs prescribed by generic name and from the national essential drugs list was 74 (22.83%) and 188 (58.02%) respectively. Biguanides were used in 176 (87.56%) patients.
These findings were similar to some other studies conducted in similar settings. In most patients, combination drug therapy was more prevalent. Among combination therapy, two drug combinations were more prevalent.
diabetes mellitus; drug combinations; outpatients; teaching hospital.
评估医院的抗糖尿病药物使用模式是一项重要的活动，有助于促进药物的合理使用，并可能提出改善处方习惯的措施。本研究旨在调查在一家三级保健中心的门诊部就诊的糖尿病患者中联合治疗的使用情况。
在获得机构审查委员会（协议号：IRC-LMC-01/R-022）批准后，于 2022 年 3 月 2 日至 6 月 30 日期间，对内科的 201 名糖尿病患者进行了为期四个月的描述性横断面研究。包括在处方中至少开一种抗糖尿病药物的糖尿病患者。收集了社会人口统计学特征、临床特征和抗糖尿病药物使用模式相关数据。使用方便抽样。计算了点估计值和 95%置信区间。
在 201 名患者中，有 134 名（66.66%）（60.14-73.18，95%置信区间）患者接受了联合治疗。最常见的联合治疗是二甲双胍 500mg 和西他列汀 50mg。共使用了 324 种抗糖尿病药物。每位患者平均开 1.6±0.7 种药物。按通用名和国家基本药物目录开的抗糖尿病药物分别为 74 种（22.83%）和 188 种（58.02%）。176 名（87.56%）患者使用了双胍类药物。
这些发现与在类似环境中进行的其他一些研究相似。在大多数患者中，联合药物治疗更为普遍。在联合治疗中，两种药物的联合更为普遍。
糖尿病；药物联合；门诊病人；教学医院。
